Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: The evolving role of Bcr-Abl mutations and mutational analysis

Pharmacogenomics

Volumn 13, Issue 11, 2012, Pages 1271-1284

  Soverini, Simona ^a   Martinelli, Giovanni ^a   Rosti, Gianantonio ^a   Iacobucci, Ilaria ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bcr Abl kinase domain mutations; chronic myeloid leukemia; dasatinib; imatinib; nilotinib; resistance

Indexed keywords

1 [3 TERT BUTYL 1 (6 QUINOLINYL) 1H PYRAZOL 5 YL] 3 [2 FLUORO 4 [[2 (METHYLCARBAMOYL) 4 PYRIDINYL]OXY]PHENYL]UREA; ALPHA INTERFERON; BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO ACID SUBSTITUTION; ARTICLE; BCR ABL GENE; BLAST CELL CRISIS; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FUSION GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IC 50; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; PHARMACOGENOMICS; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PROTEIN CONFORMATION;

CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84865467990     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.103     Document Type: Article

References (119)

1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J. Natl Cancer Inst. 25, 85-109 (1960).
2. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405), 290-293 (1973).
3. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93-99 (1984). (Pubitemid 14155374)
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science 247(4946), 1079-1082 (1990).
5. Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8(5), 935-942 (2002). (Pubitemid 34520420)
6. Soverini S, Martinelli G, Iacobucci I, Baccarani M. Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev. Anticancer Ther. 8(6), 853-864 (2008).
7. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876-880 (2001). (Pubitemid 32743979)
8. Zhou T, Parillon L, Li F et al. Crystal structure of the T315I mutant of Abl kinase. Chem. Biol. Drug Des. 70(3), 171-181 (2007). (Pubitemid 47305404)
9. Hochhaus A, Kreil S, Corbin A et al. Roots of clinical resistance to STI-571 cancer therapy. Science 293(5538), 2163 (2001).
10. Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 293(5538), 2163 (2001).
11. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2), 117-125 (2002). (Pubitemid 41039112)
12. Soverini S, Colarossi S, Gnani A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12(24), 7374-7379 (2006). (Pubitemid 46095411)
13. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8(11), 1018-1029 (2007). (Pubitemid 47629897)
14. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101(11), 4611-4614 (2003). (Pubitemid 36857835)
15. Greenman C, Stephens P, Smith R et al. Patterns of somatic mutation in human cancer genomes. Nature 446(7132), 153-158 (2007). (Pubitemid 46398669)
16. Noens L, van Lierde MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22), 5401-5411 (2009).
17. Marin D, Bazeos A, Mahon FX et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 28(14), 2381-2388 (2010).
18. Ibrahim AR, Eliasson L, Apperley JF et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14), 3733-3736 (2011).
19. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk. Res. 35(5), 626-630 (2011).
20. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117(8), E75-E87 (2011).
21. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 44(9), 879-894 (2005). (Pubitemid 41252840)
22. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12), 3739-3745 (2004). (Pubitemid 39564452)
23. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 106(3), 1133-1134 (2005).
24. White DL, Saunders VA, Dang P et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity. Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110(12), 4064-4072 (2007). (Pubitemid 350248463)
25. Mahon FX, Belloc F, Lagarde V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101(6), 2368-2373 (2003). (Pubitemid 36304670)
26. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16(11), 2190-2196 (2002). (Pubitemid 35331833)
27. Donato NJ, Wu JY, Stapley J et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2), 690-698 (2003). (Pubitemid 36077594)
28. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. 279(33), 34227-34239 (2004). (Pubitemid 39318046)
29. Wu J, Meng F, Kong LY et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J. Natl Cancer Inst. 100(13), 926-939 (2008). (Pubitemid 351957515)
30. Lange T, Park B, Willis SG, Deininger MW. BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle 4(12), 1761-1766 (2005). (Pubitemid 41827322)
31. Khorashad JS, Anand M, Marin D et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 20(4), 658-663 (2006).
32. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl Acad. Sci. USA 102(27), 9714-9719 (2005). (Pubitemid 40981746)
33. Ernst T, Erben P, Muller MC et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 93(2), 186-192 (2008). (Pubitemid 351397706)
34. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100(3), 1014-1018 (2002). (Pubitemid 34832631)
35. Willis SG, Lange T, Demehri S et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106(6), 2128-2137 (2005). (Pubitemid 41291730)
36. Soverini S, Vitale A, Poerio A et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 96(4), 552-557 (2011).
37. Gruber FX, Lamark T, Anonli A et al. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 19(12), 2159-2165 (2005). (Pubitemid 41741610)
38. Hayette S, Michallet M, Baille ML, Magaud JP, Nicolini FE. Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. Leuk. Res. 29(9), 1073-1077 (2005). (Pubitemid 40982602)
39. Hanfstein B, Muller MC, Kreil S et al. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 96(3), 360-366 (2011).
40. Griswold IJ, MacPartlin M, Bumm T et al. Kinase domain mutants of BCR-ABL exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell Biol. 26(16), 6082-6093 (2006). (Pubitemid 44204527)
41. Skaggs BJ, Gorre ME, Ryvkin A et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc. Natl Acad. Sci. USA 103(51), 19466-19471 (2006). (Pubitemid 46026054)
42. Miething C, Feihl S, Mugler C et al. The BCR-ABL mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 20(4), 650-657 (2006).
43. Sherbenou DW, Wong MJ, Humayun A et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 21(3), 489-493 (2007).
44. Soverini S, Martinelli G, Amabile M et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin. Chem. 50(7), 1205-1213 (2004). (Pubitemid 38824229)
45. Ernst T, Gruber FX, Pelz-Ackermann O et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica 94(9), 1227-1235 (2009).
46. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359(9305), 487-491 (2002). (Pubitemid 34164296)
47. Radich JP. The biology of CML blast crisis. Hematol. Am. Soc. Hematol. Educ. Prog. 384-391 (2007).
48. Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27(35), 6041-6051 (2009).
49. Soverini S, Gnani A, De Benedittis C et al. Validation of the New European LeukemiaNet (ELN) recommendations for Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia: an analysis of the GIMEMA CML Working Party Studies. Blood 118(21), 112 (2011).
50. Kantarjian HM, Hochhaus A, Saglio G et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 12(9), 841-851 (2011).
51. Hazarika M, Jiang X, Liu Q et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin. Cancer Res. 14(17), 5325-5331 (2008).
52. Brave M, Goodman V, Kaminskas E et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 14(2), 352-359 (2008). (Pubitemid 351226100)
53. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2), 129-141 (2005). (Pubitemid 40248339)
54. Manley PW, Stiefl N, Cowan-Jacob SW et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg. Med. Chem. 18(19), 6977-6986 (2010).
55. Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47(27), 6658-6661 (2004). (Pubitemid 40053752)
56. Tokarski JS, Newitt JA, Chang CY et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66(11), 5790-5797 (2006). (Pubitemid 43927133)
57. Vajpai N, Strauss A, Fendrich G et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J. Biol. Chem. 283(26), 18292-18302 (2008).
58. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682), 399-401 (2004). (Pubitemid 38938156)
59. O'Hare T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65(11), 4500-4505 (2005). (Pubitemid 40740783)
60. Lee TS, Potts SJ, Kantarjian H, Cortes J, Giles F, Albitar M. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer 112(8), 1744-1753 (2008). (Pubitemid 351536834)
61. Iacob RE, Pene-Dumitrescu T, Zhang J, Gray NS, Smithgall TE, Engen JR. Conformational disturbance in Abl kinase upon mutation and deregulation. Proc. Natl Acad. Sci. USA 106(5), 1386-1391 (2009).
62. Soverini S, Martinelli G, Colarossi S et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J. Clin. Oncol. 24(33), E51-E52 (2006).
63. Soverini S, Colarossi S, Gnani A et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92(3), 401-404 (2007). (Pubitemid 350143551)
64. Soverini S, Martinelli G, Colarossi S et al. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific Bcr-Abl mutants in Ph+ ALL. Lancet Oncol. 8(3), 273-274 (2007). (Pubitemid 46291717)
65. Soverini S, Gnani A, Colarossi S et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second-or third-line tyrosine kinase inhibitors. Blood 114(10), 2168-2171 (2009).
66. Hughes T, Saglio G, Branford S et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J. Clin. Oncol. 27(25), 4204-4210 (2009).
67. Muller MC, Cortes JE, Kim DW et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114(24), 4944-4953 (2009).
68. Cortes J, Jabbour E, Kantarjian H et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12), 4005-4011 (2007). (Pubitemid 350248456)
69. Jabbour E, Jones D, Kantarjian HM et al. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10), 2037-2043 (2009).
70. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl Acad. Sci. USA 102(9), 3395-3400 (2005). (Pubitemid 40328056)
71. Shah NP, Skaggs BJ, Branford S et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117(9), 2562-2569 (2007). (Pubitemid 47494357)
72. Breccia M, Frustaci AM, Cannella L et al. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? Cancer Chemother. Pharmacol. 64(1), 195-197 (2009).
73. Parker WT, Lawrence RM, Ho M et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J. Clin. Oncol. 29(32), 4250-4259 (2011).
74. Cortes J, Kantarjian H, Baccarani M et al. A Phase 1/2 Study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 108, 168S (2006).
75. Cortes JE, Kantarjian HM, Brummendorf TH et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17), 4567-4576 (2011).
76. Khoury HJ, Cortes JE, Kantarjian HM et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119(15), 3403-3412 (2012).
77. Kantarjian H, le Coutre P, Cortes J et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 116(11), 2665-2672 (2010).
78. Cortes J, Maru A, De Souza C et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia-BELA trial: 24-month follow-up. Blood 118, 455 (2011).
79. Kantarjian HM, Shah NP, Cortes JE et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119(5), 1123-1129 (2012).
80. Puttini M, Coluccia AM, Boschelli F et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 66(23), 11314-11322 (2006). (Pubitemid 46009962)
81. Kimura S, Naito H, Segawa H et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106(12), 3948-3954 (2005). (Pubitemid 41739036)
82. Quintas-Cardama A, Kantarjian H, Garcia-Manero G et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109(2), 248-255 (2007). (Pubitemid 46106239)
83. O'Hare T, Shakespeare WC, Zhu X et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5), 401-412 (2009).
84. Eide CA, Adrian LT, Tyner JW et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 71(9), 3189-3195 (2011).
85. Chan WW, Wise SC, Kaufman MD et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 19(4), 556-568 (2011).
86. Cortes J, Talpaz M, Kantarijan H et al. A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation. Blood 118(21), 601 (2011).
87. Cortes J, Kim DW, Pinilla-Ibarz J et al. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Blood 118(21), 109 (2011).
88. Rosti G, Palandri F, Castagnetti F et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 114(24), 4933-4938 (2009).
89. Gugliotta G, Castagnetti F, Breccia M et al. Early CP CML, nilotinib 400 mg twice daily frontline: beyond 3 years, results remain excellent and stable (A GIMEMA CML Working Party Trial). Blood 118(21), 2756 (2011).
90. Cortes JE, Jones D, O'Brien S et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol. 28(3), 392-397 (2010).
91. Quintas-Cardama A, Kantarijan H, Luthra R et al. Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in early chronic phase (CML-CP). Blood 118(21), 454 (2011).
92. Hiwase DK, Saunders V, Hewett D et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin. Cancer Res. 14(12), 3881-3888 (2008).
93. Dohse M, Scharenberg C, Shukla S et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab. Dispos. 38(8), 1371-1380 (2010).
94. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112(8), 3348-3354 (2008).
95. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2), 473-475 (2003). (Pubitemid 36077567)
96. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin. Cancer Res. 9(6), 2092-2097 (2003). (Pubitemid 36687630)
97. Kantarjian HM, Larson RA, Guilhot F et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115(3), 551-560 (2009).
98. Jabbour E, Kantarjian HM, Jones D et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113(10), 2154-2160 (2009).
99. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6), 2303-2309 (2007). (Pubitemid 46425867)
100. Guilhot F, Apperley J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood 109(10), 4143-4150 (2007). (Pubitemid 46743375)
101. Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood 109(8), 3207-3213 (2007). (Pubitemid 46572505)
102. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10), 3540-3546 (2007). (Pubitemid 350159618)
103. Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 117(3), 755-763 (2011).
104. Soverini S, Hochhaus A, Nicolini FE et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5), 1208-1215 (2011).
105. Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9), 3472-3475 (2002). (Pubitemid 34525335)
106. Roumiantsev S, Shah NP, Gorre ME et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl Acad. Sci. USA 99(16), 10700-10705 (2002).
107. Khorashad JS, Milojkovic D, Mehta P et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 111(4), 2378-2381 (2008). (Pubitemid 351451447)
108. Irving JA, O'Brien S, Lennard AL, Minto L, Lin F, Hall AG. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib. Clin. Chem. 50(7), 1233-1237 (2004). (Pubitemid 38824234)
109. Branford S, Rudzki Z, Walsh S et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102(1), 276-283 (2003). (Pubitemid 36759665)
110. Kreuzer KA, Le Coutre P, Landt O et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann. Hematol. 82(5), 284-289 (2003). (Pubitemid 36701422)
111. Al-Ali HK, Heinrich MC, Lange T et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol. J. 5(1), 55-60 (2004). (Pubitemid 38262791)
112. Soverini S, Martinelli G, Rosti G et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J. Clin. Oncol. 23(18), 4100-4109 (2005). (Pubitemid 46211315)
113. Lahaye T, Riehm B, Berger U et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103(8), 1659-1669 (2005). (Pubitemid 40490027)
114. Sorel N, Chazelas F, Brizard A, Chomel JC. Double-gradient-denaturing- gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients. Clin. Chem. 51(7), 1263-1266 (2005). (Pubitemid 43079409)
115. Nicolini FE, Corm S, Le QH et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 20(6), 1061-1066 (2006). (Pubitemid 43797298)
116. le Coutre P, Ottmann OG, Giles F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111(4), 1834-1839 (2008). (Pubitemid 351451490)
117. Ernst T, Hoffmann J, Erben P et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 93(9), 1389-1393 (2008).
118. Hochhaus A, Baccarani M, Deininger M et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22(6), 1200-1206 (2008). (Pubitemid 351833788)
119. Apperley JF, Cortes JE, Kim DW et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J. Clin. Oncol. 27(21), 3472-3479 (2009).